The Cigna Group

No forensic scores are on file for this company, so this synthesis gives no Beneish M-Score, Piotroski F-Score, Altman Z-Score, or Fog Index value, and none should be inferred from the figures here. Readers may want to look for those screens in a dedicated analysis before drawing conclusions about reporting quality. The 2025 numbers show a company growing its top line faster than its operating profit, with net income up sharply from a lower 2024 base. The 2018 revenue figure of $48.65 billion is far below adjacent years, so multi-year trend comparisons from that point need care. Capital allocation disclosures in the Q1 2026 10-Q show that no shares were bought under the publicly announced repurchase program during January through March 2026, with $6,730 million still available under that authorization. Employees tendered 268,400 shares in the quarter for tax and exercise obligations. The filing also discloses a Rule 10b5-1 plan adopted February 6, 2026 by Chair and CEO David Cordani, covering performance awards that may vest from 0% to 200% of 62,366 target shares and up to 212,543 vested options, running through April 30, 2027. The company states the plan was entered during an open trading window. Management reports disclosure controls as effective and no material changes to internal control over financial reporting in the quarter. Legal matters are incorporated by reference from Note 14, which is not in the excerpt provided, so that exposure cannot be assessed here.

Catalyst.Revenue is the clearest driver in the data: $274.9 billion in 2025 versus $247.12 billion in 2024, an increase of about 11.2%. The 10-K describes two segments: Evernorth Health Services, which includes Pharmacy Benefit Services and Specialty and Care Services, and Cigna Healthcare, which includes U.S. Healthcare and International Health. The 10-K frames the company's direction around its Commitments to Better program, with five focus areas including easier access to care and better value. The 10-Q MD&A excerpt provided does not include segment-level results, so the growth cannot be attributed to a specific segment from the data on file.

Hidden risk.The most easily missed tension is between revenue and profit. Revenue grew about 11.2% in 2025, yet operating income fell from $9.42 billion in 2024 to $9.2 billion in 2025, a decline of about 2.3%. Operating income equals about 3.35% of 2025 revenue. Net income rose to $5.96 billion from $3.43 billion, a gain of about 73.8%, but the data on file does not explain how net income rose while operating income fell, so readers may want to check the income statement and notes for non-operating items and taxes. The 10-Q risk-factor section refers back to the 10-K, and the excerpt provided is mostly forward-looking statement language.